The Real Impact of Peripheral Artery Disease in TAVR

Courtesy of Dr. Carlos Fava.

The real incidence of peripheral artery (PAD) disease in TAVR remains unclear. Different reports still estimate it is between 10 and 46%, but they have shown it has a negative impact in evolution.

Protrusión de placa en angioplastia carotidea ¿Qué riesgo implica y cómo prevenirlo?

51,685 TAVR patients were analyzed. 12,740 of these patients presented PAD (24.6%).

PAD patients tended to be younger, mostly men, smokers, hypertensive, with a history of cardiovascular and carotid disease, chronic obstructive pulmonary disease (COPD), kidney function deterioration and cardiovascular revascularization. There were no differences in obesity and diabetes. In this group, TAVR was done more often in university hospitals.


Read also: ESC 2019 | How Benign Is Moderate Aortic Stenosis?


At hospital level, there were no differences in mortality, need for pacemaker, acute myocardial infarction (AMI), or conversion to surgery. But the presence of PAD was associated to vascular complications [8.6 vs. 5.3%, OR 1.80 (1.50–2.16), p < 0.001], major bleeding [10.8 vs. 8.8%, OR 1.20 (1.09–1.34), p < 0.001], kidney function deterioration [18.2 vs. 15.6%, OR 1.19 (1.05–1.36), p=0.007], cardiac complications [9.4 vs. 8.2%, OR 1.21 (1.01–1.44), p=0.03], stroke [3.2 vs. 2.7%, OR 1.39(1.10–1.75), p=0.005] and longer in-hospital stay [7.23 (0.14) days vs. 7.11 (0.1) days, p < 0.001].

Conclusion

The presence of PAD in TAVR is 25% approximately. This disease was not associated to increased in-hospital mortality, but it was associated to higher risk of vascular complications, major bleeding, kidney function deterioration, stroke, cardiac complications and longer in-hospital stay.

Courtesy of Dr. Carlos Fava.


Original title: Association of peripheral artery disease with in-hospital outcomes after endovascular transcatheter aortic valve replacement.

Reference; Divyanshu Mohananey, et, al. Catheter Cardiovasc Interv 2019;94:249-255.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...